https://www.todayinfinance.com/article/946937689-vera-therapeutics-announces-origin-3-final-efficacy-analysis-of-trutakna-atacicept-vymj-in-iga-nephropathy-will-be-a-featured-late-breaking-oral
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA...
veratherapeuticsannouncesoriginfinal
https://www.eurekastatenews.com/article/946937689-vera-therapeutics-announces-origin-3-final-efficacy-analysis-of-trutakna-atacicept-vymj-in-iga-nephropathy-will-be-a-featured-late-breaking-oral
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA...
Eureka State News is an online news publication focusing on the California: Following the news from California
veratherapeuticsannouncesoriginfinal
https://www.ajmc.com/view/atacicept-shows-encouraging-safety-profile-in-iga-nephropathy-richard-lafayette-md
Atacicept Shows Encouraging Safety Profile in IgA Nephropathy: Richard Lafayette, MD | AJMC
Oct 8, 2026 - ORIGIN trial data suggest atacicept (Trutakna; Vera Therapeutics) is well tolerated in IgA nephropathy, with follow-up needed to assess long-term kidney...
safety profileiga nephropathyataciceptshowsencouraging